Cargando…

Flavonoids as Human Intestinal α-Glucosidase Inhibitors

Certain flavonoids can influence glucose metabolism by inhibiting enzymes involved in carbohydrate digestion and suppressing intestinal glucose absorption. In this study, four structurally-related flavonols (quercetin, kaempferol, quercetagetin and galangin) were evaluated individually for their abi...

Descripción completa

Detalles Bibliográficos
Autores principales: Barber, Elizabeth, Houghton, Michael J., Williamson, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392382/
https://www.ncbi.nlm.nih.gov/pubmed/34441720
http://dx.doi.org/10.3390/foods10081939
_version_ 1783743489878523904
author Barber, Elizabeth
Houghton, Michael J.
Williamson, Gary
author_facet Barber, Elizabeth
Houghton, Michael J.
Williamson, Gary
author_sort Barber, Elizabeth
collection PubMed
description Certain flavonoids can influence glucose metabolism by inhibiting enzymes involved in carbohydrate digestion and suppressing intestinal glucose absorption. In this study, four structurally-related flavonols (quercetin, kaempferol, quercetagetin and galangin) were evaluated individually for their ability to inhibit human α-glucosidases (sucrase, maltase and isomaltase), and were compared with the antidiabetic drug acarbose and the flavan-3-ol(−)-epigallocatechin-3-gallate (EGCG). Cell-free extracts from human intestinal Caco-2/TC7 cells were used as the enzyme source and products were quantified chromatographically with high accuracy, precision and sensitivity. Acarbose inhibited sucrase, maltase and isomaltase with IC(50) values of 1.65, 13.9 and 39.1 µM, respectively. A similar inhibition pattern, but with comparatively higher values, was observed with EGCG. Of the flavonols, quercetagetin was the strongest inhibitor of α-glucosidases, with inhibition constants approaching those of acarbose, followed by galangin and kaempferol, while the weakest were quercetin and EGCG. The varied inhibitory effects of flavonols against human α-glucosidases depend on their structures, the enzyme source and substrates employed. The flavonols were more effective than EGCG, but less so than acarbose, and so may be useful in regulating sugar digestion and postprandial glycaemia without the side effects associated with acarbose treatment.
format Online
Article
Text
id pubmed-8392382
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83923822021-08-28 Flavonoids as Human Intestinal α-Glucosidase Inhibitors Barber, Elizabeth Houghton, Michael J. Williamson, Gary Foods Article Certain flavonoids can influence glucose metabolism by inhibiting enzymes involved in carbohydrate digestion and suppressing intestinal glucose absorption. In this study, four structurally-related flavonols (quercetin, kaempferol, quercetagetin and galangin) were evaluated individually for their ability to inhibit human α-glucosidases (sucrase, maltase and isomaltase), and were compared with the antidiabetic drug acarbose and the flavan-3-ol(−)-epigallocatechin-3-gallate (EGCG). Cell-free extracts from human intestinal Caco-2/TC7 cells were used as the enzyme source and products were quantified chromatographically with high accuracy, precision and sensitivity. Acarbose inhibited sucrase, maltase and isomaltase with IC(50) values of 1.65, 13.9 and 39.1 µM, respectively. A similar inhibition pattern, but with comparatively higher values, was observed with EGCG. Of the flavonols, quercetagetin was the strongest inhibitor of α-glucosidases, with inhibition constants approaching those of acarbose, followed by galangin and kaempferol, while the weakest were quercetin and EGCG. The varied inhibitory effects of flavonols against human α-glucosidases depend on their structures, the enzyme source and substrates employed. The flavonols were more effective than EGCG, but less so than acarbose, and so may be useful in regulating sugar digestion and postprandial glycaemia without the side effects associated with acarbose treatment. MDPI 2021-08-20 /pmc/articles/PMC8392382/ /pubmed/34441720 http://dx.doi.org/10.3390/foods10081939 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Barber, Elizabeth
Houghton, Michael J.
Williamson, Gary
Flavonoids as Human Intestinal α-Glucosidase Inhibitors
title Flavonoids as Human Intestinal α-Glucosidase Inhibitors
title_full Flavonoids as Human Intestinal α-Glucosidase Inhibitors
title_fullStr Flavonoids as Human Intestinal α-Glucosidase Inhibitors
title_full_unstemmed Flavonoids as Human Intestinal α-Glucosidase Inhibitors
title_short Flavonoids as Human Intestinal α-Glucosidase Inhibitors
title_sort flavonoids as human intestinal α-glucosidase inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392382/
https://www.ncbi.nlm.nih.gov/pubmed/34441720
http://dx.doi.org/10.3390/foods10081939
work_keys_str_mv AT barberelizabeth flavonoidsashumanintestinalaglucosidaseinhibitors
AT houghtonmichaelj flavonoidsashumanintestinalaglucosidaseinhibitors
AT williamsongary flavonoidsashumanintestinalaglucosidaseinhibitors